|
|
|
|
| LEADER |
02629nam a2200241 u 4500 |
| 001 |
EB002072237 |
| 003 |
EBX01000000000000001212327 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220923 r ||| eng |
| 020 |
|
|
|a 9789240048126
|
| 020 |
|
|
|a 9789240048133
|
| 245 |
0 |
0 |
|a WHO consolidated guidelines on tuberculosis, Module 4: Treatment : drug-susceptible tuberculosis treatment
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a drug-susceptible tuberculosis treatment
|
| 260 |
|
|
|a Geneva, Switzerland
|b World Health Organization
|c 2022, [2022]
|
| 300 |
|
|
|a 1 PDF file (xii, 52 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a World Health Organization
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK581329
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community
|